GlaxoSmithKline, Theravance Withdraw License Application for RELVAR ELLIPTA in Japan

GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX ) today announced that the licence application for the use of fluticasone furoate (FF) and vilanterol (VI) (proposed brand name RELVAR™ ELLIPTA™) in patients with chronic obstructive pulmonary disease (COPD) has been withdrawn from the current Japanese New Drug Application (JNDA).